February 27, 2019 Articles

Top Five Drug and Device Developments of 2018

The proposed 510(k) overhaul, admissibility of 510(k) evidence, tort remedies for generic consumers, third-party pressure on plaintiffs, and claim separation in multidistrict litigation.

By Christine Kain, Patrick Reilly, Isabelle Chammas, and Joe Price

It’s that time of year again when we pause, reflect, and look forward to the year ahead. In this retrospective, we consider the past year’s legal developments in the drug and medical device sphere, with brief summaries of the top five we believe to have significant implications for our clients and colleagues. 

Premium Content For:
  • Litigation Section
Join - Now